Theravance Biopharma (NASDAQ:TBPH) Earns Neutral Rating from HC Wainwright

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $17.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $15.00.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. BTIG Research cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. TD Cowen lifted their price objective on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Finally, Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. Eight investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.40.

Theravance Biopharma Stock Up 0.4%

Shares of NASDAQ TBPH opened at $17.00 on Tuesday. Theravance Biopharma has a 12-month low of $10.82 and a 12-month high of $21.03. The firm’s 50-day simple moving average is $16.59 and its 200 day simple moving average is $17.27. The company has a market cap of $876.35 million, a price-to-earnings ratio of 7.73 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The company had revenue of $17.70 million during the quarter. On average, equities analysts expect that Theravance Biopharma will post 1.54 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Eli Samaha sold 273,871 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.23, for a total value of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the sale, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 350,011 shares of company stock worth $6,008,309. 7.65% of the stock is currently owned by company insiders.

Institutional Trading of Theravance Biopharma

Several hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership bought a new position in Theravance Biopharma during the third quarter worth about $10,611,000. Pacer Advisors Inc. bought a new stake in shares of Theravance Biopharma in the fourth quarter worth about $6,342,000. Janus Henderson Group PLC raised its position in shares of Theravance Biopharma by 214.8% during the fourth quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock worth $7,493,000 after purchasing an additional 273,288 shares during the period. Two Sigma Investments LP raised its position in shares of Theravance Biopharma by 1,199.9% during the third quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after purchasing an additional 213,480 shares during the period. Finally, HRT Financial LP lifted its holdings in shares of Theravance Biopharma by 892.8% during the 4th quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock valued at $4,356,000 after purchasing an additional 209,397 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.